Aktuelles aus der Forschung

• Literatur

• 1 Huynh JL et al. Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains. Nat Neurosci 2014; 17: 121-130
• 2 Pedre X et al. Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions. J Neurosci 2011; 31: 3435-3445
• 3 Moscarello MA et al. Myelin in multiple sclerosis is developmentally immature. J Clin Invest 1994; 94: 146-154
• 4 Deshmukh VA et al. A regenerative approach to the treatment of multiple sclerosis. Nature 2013; 502: 327-332
• 5 Stoppe M et al. Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis: current status and preliminary safety analysis. DGN; 2013
• 6 Popescu BF et al. Absence of cortical demyelination in neuromyelitis optica. Neurology 2010; 75: 2103-2109
• 7 Saji E et al. Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol 2013; 73: 65-76
• 8 Fine AJ et al. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann Neurol 2013;
• 9 Warnke C et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. JNNP 2013; 84: 1199-1205
• 10 Schwab N et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013; 81: 865-871
• 11 Dahlhaus S et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. JNNP 2013; 84: 1068-1074